DocTIS single cell atlas to be presented at ACR Convergence 2025
ACR Convergence 2025, the annual meeting of the American College of Rheumatology (ACR), will take place from October 24–29, 2025 at the McCormick Place Convention Center in Chicago, USA. As the world’s leading rheumatology event, ACR Convergence brings together thousands of clinicians, researchers, and industry experts to advance scientific knowledge and clinical practice.
This year, the DocTIS project will present its study “DocTIS: A single-cell RNA-seq atlas of drug response to targeted therapies”. The work will be showcased by Dr. Antonio Julià, head of the rheumatology research group at Vall d’Hebron Research Institute (VHIR), during the Genetics, genomics & proteomics poster session on Sunday, October 26, 2025 (10:30 am – 12:30 pm).
This DocTIS study aims to understand why patients with immune-mediated inflammatory diseases (IMIDs) respond differently to targeted therapies. By applying single-cell RNA sequencing (scRNA-seq) across six IMIDs including psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, rheumatoid arthritis and systemic lupus erythematosus, the project has created a large-scale atlas of more than two million immune cells.
Findings from this work reveal that IMIDs differ widely at both the cellular and molecular levels and that the effects of targeted therapies are largely disease-specific. By identifying unique immune features linked to treatment response, the DocTIS atlas provides a valuable resource to better understand disease heterogeneity, mechanisms of drug efficacy and, consequently, support the development of more precise and personalized therapies for patients.
This research has been developed by DocTIS partners including Vall d’Hebron Research Institute (VHIR), Charité – Universitätsmedizin Berlin, the University of Verona, the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), HudsonAlpha Institute for Biotechnology, Cardiff University, the National Center for Genomic Analysis (CNAG) amd IMIDomics Inc., working in collaboration with hospitals across Spain through the IMID Consortium.
Find the full abstract here: https://acrabstracts.org/abstract/DocTIS-a-single-cell-rna-seq-atlas-of-drug-response-to-targeted-therapies/
About the ACR Convergence
Founded in 1934, the American College of Rheumatology (ACR) is a professional association representing more than 10,500 physicians, health professionals, researchers and scientists worldwide. The ACR provides education, research support, advocacy and practice management resources to advance rheumatology and improve patient care.
ACR Convergence is the organization’s flagship annual meeting. In 2024, the event welcomed over 13,600 registrants, including more than 10,400 scientific attendees, confirming its role as the premier global gathering in rheumatology.
Full program: https://rheumatology.org/annual-meeting-program
